MAPRE3

Across TCGA pan-cancer cohorts, MAPRE3 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAPRE3 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAPRE3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAPRE3 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where MAPRE3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.601	0.847	<.001	34	view →
LSCC	OS	Quartile	All	0.788	0.923	.016	15	view →
UCEC	DFS	Quartile	III,IV	0.280	1.000	.040	8	view →
GBM	DFS	Quartile	All	0.856	0.634	.021	4	view →
LUAD	OS	Tertile	III,IV	0.665	0.246	.039	2	view →
PDAC	DFS	Quartile	III,IV	1.000	0.615	.032	2	view →
HNSC	OS	Median	III,IV	0.946	1.000	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAPRE3–CCRCC (DFS)

Open the CCRCC breakdown →